Dare Bioscience Inc (DARE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Dare Bioscience Inc (DARE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7959
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dare Bioscience Inc (Dare Bioscience), formerly Cerulean Pharma Inc, is a clinical stage biopharmaceutical company that develops products for women’s reproductive health. The company, through its dynamic tumor targeting platform, creates nanoparticle drug conjugates to attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Its products include ovaprene, a clinical stage, non-hormonal contraceptive ring that provides protection over multiple weeks of use; and topical 5% sildenafil citrate cream for women with female sexual arousal disorders. The company develops and markets therapies for women in the areas of contraception, vaginal health, sexual health and fertility. Dare Bioscience is headquartered in San Diego, California, the US.

Dare Bioscience Inc (DARE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dare Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Dare Bioscience to Acquire CatSper Contraceptive Target from Hydra Biosciences 13
Venture Financing 14
Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 14
Cerulean Pharma Raises US$13 Million In Venture Financing 15
Partnerships 16
Dare Bioscience Enters into Development and Option Agreement with Orbis Biosciences 16
Cerulean Pharma Enters into Partnership with Novartis 17
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 18
Cerulean Pharma Enters into Research Agreement with GOG Foundation 19
Merger 20
Dare Bioscience to Merge with Pear Tree Pharma 20
Licensing Agreements 21
Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 21
Dare Bioscience to Enter into Licensing Agreement with Strategic Science & Technologies 23
Equity Offering 25
Dare Bioscience to Raise USD4.1 Million in Public Offering of Shares 25
Dare Bioscience to Raise Funds through Public Offering of Shares 26
Dare Bioscience Plans to Raise up to USD10 Million in Public Offering of Shares 27
Dare Bioscience Raises USD20.7 Million in Equity Financing 28
Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 29
Cerulean Pharma Raises USD40 Million in Public Offering of Shares 31
Cerulean Pharma Raises USD1 Million in Private Placement of Shares 33
Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$67 Million 34
Asset Transactions 36
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 36
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 37
Acquisition 38
Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 38
Dare Bioscience Inc – Key Competitors 39
Dare Bioscience Inc – Key Employees 40
Dare Bioscience Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Corporate Communications 42
Sep 17, 2018: Dare Bioscience names Greg Matz as board director 42
Jun 06, 2018: Dare Bioscience Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer 43
May 08, 2018: Dare Bioscience Expands Leadership Team, Appointing John Fair to Chief Business Officer 44
Apr 11, 2018: Jessica Grossman Joins Dare Bioscience Board of Directors 45
Jul 20, 2017: Daré Bioscience trading on The NASDAQ Capital Market under the symbol “DARE” 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dare Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dare Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dare Bioscience to Acquire CatSper Contraceptive Target from Hydra Biosciences 13
Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 14
Cerulean Pharma Raises US$13 Million In Venture Financing 15
Dare Bioscience Enters into Development and Option Agreement with Orbis Biosciences 16
Cerulean Pharma Enters into Partnership with Novartis 17
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 18
Cerulean Pharma Enters into Research Agreement with GOG Foundation 19
Dare Bioscience to Merge with Pear Tree Pharma 20
Dare Bioscience Enters into Licensing Agreement with Juniper Pharma 21
Dare Bioscience to Enter into Licensing Agreement with Strategic Science & Technologies 23
Dare Bioscience to Raise USD4.1 Million in Public Offering of Shares 25
Dare Bioscience to Raise Funds through Public Offering of Shares 26
Dare Bioscience Plans to Raise up to USD10 Million in Public Offering of Shares 27
Dare Bioscience Raises USD20.7 Million in Equity Financing 28
Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 29
Cerulean Pharma Raises USD40 Million in Public Offering of Shares 31
Cerulean Pharma Raises USD1 Million in Private Placement of Shares 33
Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$67 Million 34
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 36
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 37
Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 38
Dare Bioscience Inc, Key Competitors 39
Dare Bioscience Inc, Key Employees 40
Dare Bioscience Inc, Subsidiaries 41

List of Figures
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dare Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dare Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Dare Bioscience Inc (DARE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Charter Communications Inc (CHTR):企業の財務・戦略的SWOT分析
    Charter Communications Inc (CHTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Landesbank Berlin Holding AG:企業の戦略・SWOT・財務情報
    Landesbank Berlin Holding AG - Strategy, SWOT and Corporate Finance Report Summary Landesbank Berlin Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Terumo Cardiovascular Systems Corporation:製品パイプライン分析
    Summary Terumo Cardiovascular Systems Corporation (TCSC), a subsidiary of Terumo Corporation, is a provider of medical equipment and devices for cardiac and vascular surgeries. It produces hardware products including heart-lung machines and intra-operative monitoring systems for cardiac surgeries. I …
  • NovioSense BV-医療機器分野:企業M&A・提携分析
    Summary NovioSense BV (NovioSense) is a medical device company that develops a wireless technology platform for non-invasive monitoring of disease biomarkers. The company provides NovioSense, a glucose sensor to continuously monitor glucose levels in the tear fluid and sends a wireless signal to a h …
  • Tokmanni Group Oyj (TOKMAN):企業の財務・戦略的SWOT分析
    Tokmanni Group Oyj (TOKMAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Freshfields Bruckhaus Deringer LLP:企業の戦略・SWOT・財務情報
    Freshfields Bruckhaus Deringer LLP - Strategy, SWOT and Corporate Finance Report Summary Freshfields Bruckhaus Deringer LLP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Shanghai Kehua Bio-engineering Co Ltd (002022):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Kehua Bio-engineering Co Ltd (KHB) is a medical device company that develops, manufactures and markets in vitro diagnostic devices and related products. The company’s major product portfolio includes enzyme immunoassay kits, clinical chemistry reagents, PCR kits, rapid test kits, ch …
  • AeroCentury Corp:企業の戦略・SWOT・財務分析
    AeroCentury Corp - Strategy, SWOT and Corporate Finance Report Summary AeroCentury Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Northland Power Inc (NPI)-エネルギー分野:企業M&A・提携分析
    Summary Northland Power Inc. (Northland Power) is an independent power producer. It develops, finances, builds, owns, and operates clean and green power projects in Canada and internationally. The company generates energy from natural gas, biomass, landfill gas, wind and solar sources. In thermal ge …
  • Diebold Nixdorf AG.:企業の戦略・SWOT・財務分析
    Diebold Nixdorf AG. - Strategy, SWOT and Corporate Finance Report Summary Diebold Nixdorf AG. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • TPS Eastern Africa Limited:企業の戦略・SWOT・財務情報
    TPS Eastern Africa Limited - Strategy, SWOT and Corporate Finance Report Summary TPS Eastern Africa Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Control4 Corp (CTRL):企業の財務・戦略的SWOT分析
    Control4 Corp (CTRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lydall Inc (LDL):企業の財務・戦略的SWOT分析
    Lydall Inc (LDL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • McKinsey & Company, Inc.:企業の戦略・SWOT・財務情報
    McKinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary McKinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Atmos Energy Corp:企業の財務・戦略的SWOT分析
    Atmos Energy Corp - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Magnotta Winery Corporation:企業の戦略・SWOT・財務情報
    Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report Summary Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Close Brothers Asset Management:企業の戦略・SWOT・財務情報
    Close Brothers Asset Management - Strategy, SWOT and Corporate Finance Report Summary Close Brothers Asset Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cryostar SAS:企業の戦略的SWOT分析
    Cryostar SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • CIBC Wealth Management:企業の戦略・SWOT・財務分析
    CIBC Wealth Management - Strategy, SWOT and Corporate Finance Report Summary CIBC Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析
    Summary Luye Pharma Group Ltd (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd is a drug development company that discovers, manufactures, and commercializes novel formulations, generic drugs, and pharmaceutical products. The company offers its products in the form of tablets, formulation …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆